ReShape Lifesciences (RSLS) Competitors $4.38 -0.09 (-2.01%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends RSLS vs. ABT, ISRG, SYK, BSX, MDT, BDX, EW, RMD, IDXX, and DXCMShould you be buying ReShape Lifesciences stock or one of its competitors? The main competitors of ReShape Lifesciences include Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), ResMed (RMD), IDEXX Laboratories (IDXX), and DexCom (DXCM). These companies are all part of the "health care equipment" industry. ReShape Lifesciences vs. Abbott Laboratories Intuitive Surgical Stryker Boston Scientific Medtronic Becton, Dickinson and Company Edwards Lifesciences ResMed IDEXX Laboratories DexCom ReShape Lifesciences (NASDAQ:RSLS) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Which has better earnings and valuation, RSLS or ABT? Abbott Laboratories has higher revenue and earnings than ReShape Lifesciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReShape Lifesciences$8.18M0.38-$11.39MN/AN/AAbbott Laboratories$41.22B4.81$5.72B$3.2934.72 Do institutionals and insiders believe in RSLS or ABT? 22.1% of ReShape Lifesciences shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.1% of ReShape Lifesciences shares are owned by insiders. Comparatively, 1.1% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community prefer RSLS or ABT? Abbott Laboratories received 536 more outperform votes than ReShape Lifesciences when rated by MarketBeat users. Likewise, 69.70% of users gave Abbott Laboratories an outperform vote while only 66.11% of users gave ReShape Lifesciences an outperform vote. CompanyUnderperformOutperformReShape LifesciencesOutperform Votes39866.11% Underperform Votes20433.89% Abbott LaboratoriesOutperform Votes93469.70% Underperform Votes40630.30% Is RSLS or ABT more profitable? Abbott Laboratories has a net margin of 13.99% compared to ReShape Lifesciences' net margin of -86.36%. Abbott Laboratories' return on equity of 20.18% beat ReShape Lifesciences' return on equity.Company Net Margins Return on Equity Return on Assets ReShape Lifesciences-86.36% -179.83% -91.48% Abbott Laboratories 13.99%20.18%10.84% Do analysts prefer RSLS or ABT? Abbott Laboratories has a consensus target price of $130.71, suggesting a potential upside of 14.43%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Abbott Laboratories is more favorable than ReShape Lifesciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ReShape Lifesciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Abbott Laboratories 0 Sell rating(s) 4 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.73 Does the media refer more to RSLS or ABT? In the previous week, Abbott Laboratories had 14 more articles in the media than ReShape Lifesciences. MarketBeat recorded 15 mentions for Abbott Laboratories and 1 mentions for ReShape Lifesciences. Abbott Laboratories' average media sentiment score of 0.79 beat ReShape Lifesciences' score of 0.59 indicating that Abbott Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ReShape Lifesciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abbott Laboratories 9 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, RSLS or ABT? ReShape Lifesciences has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. SummaryAbbott Laboratories beats ReShape Lifesciences on 15 of the 16 factors compared between the two stocks. Ad Stansberry ResearchThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone" Click here to see Dan's new, urgent warning about the U.S. market for 2025. Get ReShape Lifesciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RSLS vs. The Competition Export to ExcelMetricReShape LifesciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.12M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5989.9717.17Price / Sales0.38196.061,117.23117.03Price / CashN/A57.1643.0437.86Price / Book0.155.094.784.78Net Income-$11.39M$151.83M$120.31M$225.60M7 Day Performance-7.20%-2.13%-1.92%-1.23%1 Month Performance-21.08%-4.55%13.64%0.46%1 Year Performance-74.62%8.87%28.32%15.25% ReShape Lifesciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RSLSReShape Lifesciences0.7812 of 5 stars$4.38-2.0%N/A-75.6%$3.12M$8.18M0.0050News CoverageGap DownABTAbbott Laboratories4.915 of 5 stars$113.24-0.1%$130.71+15.4%+5.3%$196.41B$41.22B34.46114,000Dividend IncreaseISRGIntuitive Surgical4.6827 of 5 stars$545.18+1.0%$550.28+0.9%+57.3%$194.18B$7.87B86.7513,676Analyst ForecastSYKStryker4.9526 of 5 stars$374.20-0.1%$404.35+8.1%+23.2%$142.65B$21.97B40.1852,000Analyst ForecastBSXBoston Scientific4.3394 of 5 stars$91.11+1.1%$95.52+4.8%+59.9%$134.28B$15.91B75.0248,000Analyst ForecastMDTMedtronic4.9527 of 5 stars$81.69-1.0%$95.27+16.6%-1.1%$104.75B$33.00B25.1495,000Analyst ForecastOptions VolumeBDXBecton, Dickinson and Company4.8876 of 5 stars$230.79+2.3%$283.50+22.8%-6.3%$66.73B$20.18B37.9774,000Analyst DowngradeInsider TradeAnalyst RevisionEWEdwards Lifesciences3.9448 of 5 stars$74.05+1.0%$79.40+7.2%-0.2%$43.67B$6.00B10.7419,800RMDResMed4.5342 of 5 stars$241.36+1.2%$227.91-5.6%+35.7%$35.43B$4.81B31.599,980Positive NewsIDXXIDEXX Laboratories4.9808 of 5 stars$432.56+0.1%$539.63+24.8%-25.4%$35.42B$3.84B41.6711,000Positive NewsDXCMDexCom4.9164 of 5 stars$76.61-0.8%$98.00+27.9%-34.8%$29.92B$3.95B46.229,600 Related Companies and Tools Related Companies ABT Alternatives ISRG Alternatives SYK Alternatives BSX Alternatives MDT Alternatives BDX Alternatives EW Alternatives RMD Alternatives IDXX Alternatives DXCM Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RSLS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReShape Lifesciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ReShape Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RSLS Stock Alerts